Drug intelligence / Profile preview

scorpion venom

Development stage
Unknown
Lead developer
Blaze Bioscience
Modality
Small Molecules, Recombinant Proteins and Enzymes, Peptides
Administration
Intravenous, Intraarticular, Topical
01

Overview

Scorpion venom is a complex natural secretion produced by various species of scorpions, containing a diverse mixture of peptides, proteins, enzymes, and small molecules. It has been used in traditional medicine for centuries and is currently under investigation for several potential therapeutic applications. Laboratory studies have identified components with antinociceptive (pain-relieving), anti-inflammatory, antimicrobial, and anticancer properties. Notably, chlorotoxin—a peptide from the deathstalker scorpion—has shown the ability to bind selectively to tumor cells and cross the blood-brain barrier; it is being developed as a targeting agent for brain tumors and as a shuttle to deliver drugs into the brain. Other peptides derived from scorpion venom have demonstrated efficacy in preclinical models of arthritis by delivering anti-inflammatory drugs directly to joint cartilage. Additionally, synthetic versions of certain venom compounds exhibit potent antibacterial activity against drug-resistant bacteria such as Staphylococcus aureus and Mycobacterium tuberculosis while sparing healthy tissue. Despite these promising findings in laboratory settings, there are no approved pharmaceutical products based on whole scorpion venom itself; marketed products like Escozine or Vidatox lack clinical evidence or regulatory approval for cancer or other diseases[1][2][5][6][7][8].

Brand names
EscozineVidatox
Other names
scorpion venomchlorotoxin (component)MiniCTX3 (synthetic peptide derivative)benzoquinones (venom-derived compounds)
02

Targets

CLCN3 (Chloride channel protein 3)MMP2 (Matrix metalloproteinase-2)KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))NaV alpha (Voltage-gated sodium channel alpha subunit family)Kir (Inward-rectifier potassium channels)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on scorpion venom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on scorpion venom.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call